Selected publications
Hoste E, Paquot A, Panin N, Horion S, El Hamdaoui H, Muccioli GG, Haufroid V, Elens L. Genetic polymorphisms in SLCO2B1 and ABCC1 conjointly modulate atorvastatin intracellular accumulation in HEK293 recombinant cell lines. Ther Drug Monit. 2022 Oct 11. Doi: 10.1097/FTD.0000000000001043. Online ahead of print
Stillemans G, Paquot A, Muccioli GG, Hoste E, Panin N, Åsberg A, Balligand JL, Haufroid V, Elens L. Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response. Clin Transl Sci. 2021 Nov 10. Online ahead of print.
Stillemans G, Djokoto HP, Delongie KA, El-Hamdaoui H, Panin N, Haufroid V, Elens L. Effect of four ABCB1 genetic polymorphisms on the accumulation of darunavir in HEK293 recombinant cell lines. Sci Rep. 2021 Apr 26;11(1):9000.
Stillemans G, Belkhir L, Vandercam B, Vincent A, Haufroid V, Elens L. Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model. Eur J Clin Pharmacol. Vol. 77, no. 4, p. 607-616 (2021).
Stillemans G, Belkhir L, Vandercam B, Vincent A, Haufroid V, Elens L. Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations. Clin Pharmacokinet. Vol. 60, no. 2, p. 177-189 (2021).
Woillard JB, Mourad M, Neely M, Capron A, van Schaik RHN, van Gelder T, Lloberas N, Hesselink DA, Marquet P, Haufroid H, Elens L. Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. Front. Pharmacol., Vol. 8, p. 358 [1-14] (2017).
Sennesael AL, Panin N, Vancraeynest C, Pochet L, Spinewine A, Haufroid V, Elens L. Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines. Sci Rep. 2018 Jul 12;8(1):10514.
Lloberas N, Hesselink DA, van Schaik RHN, Grinyò JM, Colom H, van Gelder T, Elens L. Detection of a rare CYP3A4 variant in a transplant patient characterized by a Tacrolimus poor metabolizer phenotype. Pharmacogenomics. 2018 Mar;19(4):305-310.
de Graan A J, Elens L, Sprowl J A, Sparreboom A, Friberg L E, Van der Holt B, de Raaf P J, de Bruijn P, Engels F K, Eskens F A, Wiemer E A, Verweij J, Mathijssen R H, Van Schaik R H. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res. (2013), 19: 3316-24.
Elens L, Bouamar R, Hesselink D A, Haufroid V, Van der Heiden I P, Van Gelder T, Van Schaik R H. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem. (2011), 57: 1574-83.
Elens L, Vandercam B, Yombi J-C, Lison D, Wallemacq P, Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics (2010), 11: 1223-34.